Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urothelial cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    240 result(s) found for: Urothelial cancer. Displaying page 7 of 12.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2017-000123-28 Sponsor Protocol Number: IJB-MULTI-MIME-A-2017 Start Date*: 2018-11-14
    Sponsor Name:Institut Jules Bordet
    Full Title: Multiorgan Metabolic imaging response assessment of Abemaciclib: the MiMe-A trial
    Medical condition: esophageal ADC, esophageal SCC, Cholangiocarcinoma, urothelial cancer (progressive after immunotherapy), or endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10055458 Esophageal adenocarcinoma LLT
    20.0 100000004864 10055476 Esophageal squamous cell carcinoma LLT
    20.0 100000004864 10008595 Cholangiocarcinoma NOS LLT
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    20.0 100000004864 10014735 Endometrial cancer NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004046-16 Sponsor Protocol Number: IMC-F106C-101 Start Date*: 2020-04-08
    Sponsor Name:Immunocore Ltd.
    Full Title: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Pos...
    Medical condition: HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers. Study IMC-F106C-101 will enroll participants with advanced cancers, including unresectable or metastatic melanoma, ovarian ca...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025665 Malignant melanoma of skin stage unspecified LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046769 Uterine carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004634-28 Sponsor Protocol Number: WO39613 Start Date*: 2019-07-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN CISPLATIN-INELIGIBLE PATIENTS WITH LOC...
    Medical condition: Urothelial carcinoma (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003021-19 Sponsor Protocol Number: BCPP2005-01 Start Date*: 2006-08-22
    Sponsor Name:University Of Birmingham
    Full Title: The use of selenium and vitamin E supplementation to prevent recurrence and progression of non-muscle-invasive bladder cancer
    Medical condition: Non-muscle-invasive transitional cell carcinoma of the bladder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-001633-24 Sponsor Protocol Number: D419BC00001 Start Date*: 2015-11-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in ...
    Medical condition: Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothe...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10022880 Invasive bladder cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) PL (Completed) DK (Completed) ES (Ongoing) GR (Trial now transitioned) PT (Completed) AT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001371-14 Sponsor Protocol Number: MK-3475-04B Start Date*: 2023-09-21
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as ...
    Medical condition: Locally advanced/unresectable or metastatic urothelial carcinoma previously untreated for their advanced disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003669-36 Sponsor Protocol Number: MS100070_0119 Start Date*: 2022-09-13
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with L...
    Medical condition: Advanced or metastatic urothelial carcinoma whose disease did not progress with 1L platinum-containing chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) ES (Trial now transitioned) FR (Trial now transitioned) DK (Completed) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004628-39 Sponsor Protocol Number: ABACUS-2 Start Date*: 2020-12-16
    Sponsor Name:Queen Mary University of London
    Full Title: A phase II study of neoadjuvant immune checkpoint inhibitors in urothelial cancer
    Medical condition: Tumours of the urothelial tract requiring surgery (T1 high grade-T4a of the bladder, rare histological subtypes) and upper urinary tract (high grade or high risk)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046384 Ureteral cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026426 Malignant neoplasm of renal pelvis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003808-39 Sponsor Protocol Number: MK-3475-866 Start Date*: 2019-07-01
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-Eligible ...
    Medical condition: Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002164-13 Sponsor Protocol Number: UZBRU_VHH1_3 Start Date*: 2017-01-05
    Sponsor Name:UZ Brussel
    Full Title: Quantification of 68GaNOTA-Anti-HER2 VHH1 Uptake in metastasis of Breast carcinoma and cancer patients and Assessment of Repeatability – Pilot study
    Medical condition: Breast cancer; salivary gland cancer; adenocarcinoma of the gastric body or gastro-esophageal junction; endometrial cancer; cancer of cervix uteri; Non-small cell lung cancer; biliary tract cancer;...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001679-36 Sponsor Protocol Number: ML41007 Start Date*: 2019-09-26
    Sponsor Name:Aarhus University
    Full Title: Treatment Of Metastic Bladder cancer at the time Of biochemical reLApse following radical cystectomy
    Medical condition: Biochemical relapse in patients who have undergone radical cystectomy because of muscle-invasive transitional cell carcinoma of the urinary bladder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066754 Bladder transitional cell carcinoma stage III PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003584-53 Sponsor Protocol Number: Debio1347-201 Start Date*: 2019-02-05
    Sponsor Name:Debiopharm International SA
    Full Title: A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3
    Medical condition: Three cohorts will be included consisting of subjects with biliary tract cancer (Cohort 1), urothelial cancer (Cohort 2) and all other solid tumor histologies not included in Cohorts 1-2 such as NS...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GR (Completed) AT (Completed) NL (Ongoing) GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) DK (Completed) NO (Completed) BG (Completed) FI (Completed) ES (Temporarily Halted) HR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-007591-42 Sponsor Protocol Number: SPON416-07(WCTU011) Start Date*: 2009-01-14
    Sponsor Name:Cardiff University
    Full Title: A Phase II single-arm trial to evaluate cisplatin and gemcitabine chemotherapy in combination with sunitinib for first-line treatment of patients with advancd transitional carcinoma of the urothelium.
    Medical condition: Advanced transitional cell carcinoma of the urothelium.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005003 Bladder cancer LLT
    9.1 10038517 Renal pelvis cancer NOS LLT
    9.1 10046375 Ureter cancer LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000038-33 Sponsor Protocol Number: DF6002-001 Start Date*: 2021-08-25
    Sponsor Name:Dragonfly Therapeutics, Inc.
    Full Title: A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monoth...
    Medical condition: Solid Tumor Melanoma NSCLC Triple-negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003031-29 Sponsor Protocol Number: D4191C00137 Start Date*: 2022-04-07
    Sponsor Name:AstraZeneca AB
    Full Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
    Medical condition: Post-Chemotherapy Urothelial and Non-Urothelial Carcinoma of the Urinary Tract. First-line patients with extensive disease (Stage IV) small-cell lung cancer (SCLC). Advanced or Metastatic Non Small...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061272 Malignant urinary tract neoplasm PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000272-34 Sponsor Protocol Number: L00070-IN-214-P1 Start Date*: 2011-08-29
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Phase II study assessing the maintenance treatment with vinflunine after first-line therapy with gemcitabine and cisplatin in patients with advanced or metastatic transitional cell carcinoma of the...
    Medical condition: Advanced or metastatic predominantly transitional cell carcinoma of the urothelial tract.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001377-40 Sponsor Protocol Number: MO29694 Start Date*: 2016-09-22
    Sponsor Name:Roche Farma, S.A. que representa en España a F. Hoffmann-La Roche Ltd
    Full Title: PHASE II, EXPLORATORY, MULTICENTER, NON RANDOMIZED, SINGLE AGENT COHORT STUDY TO DETERMINE BEST TUMOR RESPONSE WITH TRASTUZUMAB EMTANSINE IN HER2 OVEREXPRESSING SOLID TUMORS.
    Medical condition: Human epidermal growth factor receptor 2 (HER2) overexpressing solid tumors specifically metastatic urothelial bladder cancer (MUBC) as well as pancreas/cholangio cancer, which are locally advanced...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033575 Pancreas cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046721 Urothelial carcinoma bladder stage III LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SK (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002534-37 Sponsor Protocol Number: RAME-04 Start Date*: 2021-03-08
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: Diagnostic and predictive role of 64CuCl2 PET / CT in bladder cancer patients eligible for chemotherapy
    Medical condition: bladder cancer patients eligible for cisplatin chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003120-36 Sponsor Protocol Number: IMC-C103C-101 Start Date*: 2020-01-03
    Sponsor Name:Immunocore Limited
    Full Title: A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A*0201-positive Patients with Advanced MAGE-A4-positive Cancer
    Medical condition: Patients with metastatic/unresectable tumors of interest which include NSCLC, esophageal carcinoma, gastric carcinoma, HNSCC, urothelial carcinoma, ovarian carcinoma and synovial sarcoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10062006 HLA marker study PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030155 Oesophageal carcinoma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017770 Gastric carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002424-41 Sponsor Protocol Number: OGX-427-02 Start Date*: 2011-11-22
    Sponsor Name:OncoGenex Technologies, Inc.
    Full Title: A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
    Medical condition: Metastatic or locally inoperable, advanced (T4b, N2, N3 or M1) transitional cell carcinoma (TCC) of the urinary tract (bladder, urethra, ureter and renal pelvis)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005084 Bladder transitional cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 08:53:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA